Apollon Wealth Management’s aTyr Pharma ATYR Stock Holding History

Apollon Wealth Management’s Portfolio ATYR Stock Details ATYR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-11,900	Closed	-$9.28K	–	1672
2026 Q1	$9.28K	Sell	11,900 -1,000	-8%	-$844	﹤0.01%	1395
2025 Q4	$10.1K	Sell	12,900 -7,000	-35%	-$5.75K	﹤0.01%	1299
2025 Q3	$14.4K	Sell	19,900 -600	-3%	-$2.72K	﹤0.01%	1311
2025 Q2	$104K	Sell	20,500 -3,000	-13%	-$11.8K	﹤0.01%	1219
2025 Q1	$71K	Buy	+23,500	New	+$85.7K	﹤0.01%	1162

Other funds holding ATYR

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kalehua Capital Management Dallas, Texas $174M AUM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Apollon Wealth Management's ATYR Position: Q2 2026 in Review

Apollon Wealth Management sold out of aTyr Pharma (ATYR) in Q2 2026, closing a stake of 11,900 shares — an estimated $9.28K sold.

Apollon Wealth Management first reported a position in ATYR in Q1 2025 and held it in 5 quarters. The position peaked at $104K in Q2 2025. 90 funds tracked by Wall St. Rank hold ATYR as of Q2 2026.

Apollon Wealth Management reported no remaining aTyr Pharma position as of Q2 2026 after selling out during the quarter.
Apollon Wealth Management sold 11,900 aTyr Pharma shares in Q2 2026, an estimated $9.28K.
Apollon Wealth Management first reported a position in aTyr Pharma in Q1 2025 and held it in 5 quarters.
Apollon Wealth Management's aTyr Pharma position peaked at $104K in Q2 2025.
90 funds tracked by Wall St. Rank held aTyr Pharma as of Q2 2026.

Based on Apollon Wealth Management's 13F filing for Q2 2026, filed 23 Jul 2026.